SG121778A1 - Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway - Google Patents

Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Info

Publication number
SG121778A1
SG121778A1 SG200303599A SG200303599A SG121778A1 SG 121778 A1 SG121778 A1 SG 121778A1 SG 200303599 A SG200303599 A SG 200303599A SG 200303599 A SG200303599 A SG 200303599A SG 121778 A1 SG121778 A1 SG 121778A1
Authority
SG
Singapore
Prior art keywords
respiratory distress
viral
blockade
reversal
induced systemic
Prior art date
Application number
SG200303599A
Other languages
English (en)
Inventor
Jeff Browning
Maryann Puglielli
Rafi Ahmed
Original Assignee
Univ Emory
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Biogen Idec Inc filed Critical Univ Emory
Publication of SG121778A1 publication Critical patent/SG121778A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • C07K16/242Lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG200303599A 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway SG121778A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09

Publications (1)

Publication Number Publication Date
SG121778A1 true SG121778A1 (en) 2006-05-26

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200303599A SG121778A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Country Status (27)

Country Link
US (3) US20020001585A1 (sk)
EP (1) EP1119370B1 (sk)
JP (2) JP4713738B2 (sk)
KR (1) KR100888832B1 (sk)
CN (1) CN1200733C (sk)
AT (1) ATE329618T1 (sk)
AU (1) AU777492C (sk)
BR (1) BR9915025A (sk)
CA (1) CA2344049C (sk)
CY (1) CY1105059T1 (sk)
CZ (1) CZ20011272A3 (sk)
DE (1) DE69931944T2 (sk)
DK (1) DK1119370T3 (sk)
EA (1) EA006703B1 (sk)
EE (1) EE04661B1 (sk)
ES (1) ES2267294T3 (sk)
HU (1) HUP0103773A3 (sk)
IL (2) IL142284A0 (sk)
IS (1) IS2514B (sk)
NO (1) NO326905B1 (sk)
NZ (1) NZ510560A (sk)
PL (1) PL195264B1 (sk)
PT (1) PT1119370E (sk)
SG (1) SG121778A1 (sk)
SK (1) SK4662001A3 (sk)
TR (1) TR200100974T2 (sk)
WO (1) WO2000021558A1 (sk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DE60129010T2 (de) * 2000-04-12 2008-02-28 La Jolla Institute For Allergy And Immunology, San Diego Ligand des zelleintritt-vermittelnden proteins von herpes simplex und methoden zu dessen verwendungen
EP1641826A2 (en) * 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CN1980957A (zh) * 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 受体偶联剂及其治疗用途
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20090083958A (ko) 2006-10-20 2009-08-04 바이오겐 아이덱 엠에이 인코포레이티드 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료
EP3750554A3 (en) * 2007-09-18 2021-07-28 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003687A1 (en) * 1995-07-21 1997-02-06 Biogen, Inc. SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE
US5661004A (en) * 1990-06-27 1997-08-26 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1998017313A2 (en) * 1996-10-25 1998-04-30 Biogen, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE397665T1 (de) 1992-12-04 2008-06-15 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
CN1146442C (zh) 1995-01-26 2004-04-21 拜奥根有限公司 作为抗肿瘤剂的淋巴毒素-α/β复合体和抗淋巴毒素-β受体抗体
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
NZ510560A (en) * 1998-10-09 2003-09-26 Biogen Inc Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
AU2003248782A1 (en) * 2002-07-01 2004-01-19 Biogen Idec Ma Inc. Humanized anti-lymphotoxin beta receptor antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661004A (en) * 1990-06-27 1997-08-26 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5670149A (en) * 1990-06-27 1997-09-23 Biogen, Inc. Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
WO1997003687A1 (en) * 1995-07-21 1997-02-06 Biogen, Inc. SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE
WO1998017313A2 (en) * 1996-10-25 1998-04-30 Biogen, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"POTENTIAL BENEFITS AND RISKS OF A THERAPEUTIC INHIBITION OF THE LYMPHOTOXIN-B RECEPTOR PA" *
"ROLE OF LYMPHOTOXIN IN EXPERIMENTAL MODELS OF INFECTIOUS DISEASES" *

Also Published As

Publication number Publication date
HUP0103773A2 (hu) 2002-01-28
IL142284A0 (en) 2002-03-10
CA2344049A1 (en) 2000-04-20
ATE329618T1 (de) 2006-07-15
CZ20011272A3 (cs) 2001-09-12
PL195264B1 (pl) 2007-08-31
WO2000021558A9 (en) 2001-05-25
JP2010155852A (ja) 2010-07-15
NO326905B1 (no) 2009-03-16
CN1323223A (zh) 2001-11-21
PL347177A1 (en) 2002-03-25
CN1200733C (zh) 2005-05-11
EA006703B1 (ru) 2006-02-24
EA200100430A1 (ru) 2001-10-22
IL142284A (en) 2009-11-18
HUP0103773A3 (en) 2003-10-28
EE04661B1 (et) 2006-08-15
WO2000021558A1 (en) 2000-04-20
DK1119370T3 (da) 2006-10-02
US20020001585A1 (en) 2002-01-03
AU777492B2 (en) 2004-10-21
AU777492C (en) 2005-05-26
TR200100974T2 (tr) 2001-11-21
IS2514B (is) 2009-06-15
AU6296499A (en) 2000-05-01
NZ510560A (en) 2003-09-26
KR20010080073A (ko) 2001-08-22
DE69931944T2 (de) 2007-02-08
US7452530B2 (en) 2008-11-18
JP4713738B2 (ja) 2011-06-29
KR100888832B1 (ko) 2009-03-17
NO20011757L (no) 2001-06-08
EP1119370B1 (en) 2006-06-14
ES2267294T3 (es) 2007-03-01
CY1105059T1 (el) 2010-03-03
SK4662001A3 (en) 2001-11-06
PT1119370E (pt) 2006-09-29
US20040198635A1 (en) 2004-10-07
CA2344049C (en) 2009-12-15
IS5882A (is) 2001-03-09
BR9915025A (pt) 2001-08-14
EE200100211A (et) 2002-08-15
JP2002527403A (ja) 2002-08-27
NO20011757D0 (no) 2001-04-06
EP1119370A1 (en) 2001-08-01
US20090087403A1 (en) 2009-04-02
DE69931944D1 (de) 2006-07-27

Similar Documents

Publication Publication Date Title
SG121778A1 (en) Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
HK1030157A1 (en) Use of consensus interferon and compositions comprising consensus interferon.
EP1028715A4 (en) FORMULATION FOR NASAL SUPPORT AND METHOD OF USE THEREOF
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
AP2000001947A0 (en) Novel crystalline forms of an antiviral benzidazole compound.
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
DE69905368D1 (en) Oxydiertes thymosin beta 4
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
UA41355C2 (uk) Засіб для лікування нейро-сніду
EP1073416A4 (en) USE OF INHAL NITRIC OXIDE AS ANTI-INFLAMMATORY AGENT
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
WO2002089805A3 (en) Use of regularly scheduled high dose intravenous methotrexate therapy
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
AP2002002446A0 (en) Method for administering a phosphodiesterase 4 inhibitor.
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
HK1015692A1 (en) Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections
ITMI921235A1 (it) Oligonucleotidi antisenso ad attivita' antitumorale, composizioni farmaceutiche che li comprendono, e loro impieghi
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.
Fujita Experimental studies of stimulated brillouin scattering from KrF laser-produced plasma
ITMI931806A0 (it) Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica , loro uso e composizioni farmaceutiche che li contengono
ZA833161B (en) N2-(substituted)carboxymethyl-n6-(substituded)-lysyl and a-(e-aminoalkyl)glycyl amino acid antihypertensive agents